Trametinib (GSK1120212, SNR1611) is a US Food and Drug Administration-approved anti-cancer drug for melanoma patients to inhibit MEK1 and MEK2 simultaneously (MEK1/2 inhibitor) [29]. Here, MAP2K1 is linked to cancer.